Neuronetics, Inc.

NasdaqGM STIM

Neuronetics, Inc. Gross Profit for the Trailing 12 Months (TTM) ending September 30, 2024: USD 53.98 M

Neuronetics, Inc. Gross Profit is USD 53.98 M for the Trailing 12 Months (TTM) ending September 30, 2024, a 8.51% change year over year. Gross profit is the difference between revenue and the cost of revenue, representing the profit earned from core business operations.

Neuronetics, Inc. Gross Profit for the Trailing 12 Months (TTM) ending September 30, 2023 was USD 49.74 M, a 4.95% change year over year.
Neuronetics, Inc. Gross Profit for the Trailing 12 Months (TTM) ending September 30, 2022 was USD 47.40 M, a 7.74% change year over year.
Neuronetics, Inc. Gross Profit for the Trailing 12 Months (TTM) ending September 30, 2021 was USD 43.99 M, a 12.77% change year over year.
Neuronetics, Inc. Gross Profit for the Trailing 12 Months (TTM) ending September 30, 2020 was USD 39.01 M, a -15.29% change year over year.

Key data

Date	Gross Profit	Operating Income	EBIT	EBITDA

NasdaqGM: STIM

Neuronetics, Inc.

CEO	Mr. Keith J. Sullivan
IPO Date	June 28, 2018
Location	United States
Headquarters	3222 Phoenixville Pike
Employees	203
Sector	Health Care
Industries Pharmaceuticals Telehealth

Description

Neuronetics, Inc., a commercial stage medical technology company, designs, develops, and markets products for patients with neurohealth disorders in the United States and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder. Its NeuroStar Advanced Therapy System uses transcranial magnetic stimulation to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company sells its products through its sales and customer support team to psychiatrists. Neuronetics, Inc. was incorporated in 2001 and is headquartered in Malvern, Pennsylvania.

Key trends

Past 5 years